目的 建立硫酸沙丁胺醇雾化吸入溶液在儿科临床用药中的量化评价体系，探讨层次分析（AHP）-逼近理想解排序（TOPSIS）法评价硫酸沙丁胺醇雾化吸入溶液在儿科临床应用的合理性。方法 依据硫酸沙丁胺醇雾化吸入溶液说明书及相关文献，经药物合理应用评价小组专家研讨，制定合理用药评价标准。抽取成都市双流区妇幼保健院2023年7月—2024年12月292份使用硫酸沙丁胺醇雾化吸入溶液的临床病历资料，利用AHP法确定评价标准中二级指标的相对权重，采用TOPSIS法对该药物在儿科临床应用情况进行客观评价。结果 各二级指标的相对权重依次为0.126 7、0.109 1、0.120 0、0.095 4、0.060 4、0.042 7、0.086 9、0.068 4、0.054 5、0.037 0、0.034 4、0.076 9、0.047 6、0.039 9。硫酸沙丁胺醇雾化吸入溶液在儿科临床应用合理性较高。结论 建立的AHP-TOPSIS法评价硫酸沙丁胺醇雾化吸入溶液在儿科临床利用的合理性，为其合理用药提供指导。

Objective To establish a quantitative evaluation system for Salbutamol Sulfate Nebules Inhalation Solution in pediatric clinical medication, and to explore the rationality of AHP-TOPSIS method in evaluating the clinical application of Salbutamol Sulfate Nebules Inhalation Solution in pediatrics. Methods According to the instructions of Salbutamol Sulfate Nebules Inhalation Solution and related literature, the evaluation standard of rational drug use was formulated by the expert discussion of the evaluation group of rational drug use. The clinical medical records of 292 cases of Salbutamol Sulfate Nebules Inhalation Solution in Chengdu Shuangliu District Maternal and Child Health Hospital from July 2023 to Dec 2024 were selected. The AHP method was used to determine the relative weight of the secondary indicators in the evaluation criteria, and the TOPSIS method was used to objectively evaluate the clinical application of the drug in pediatrics. Results The relative weights of each secondary index were 0.126 7, 0.109 1, 0.120 0, 0.095 4, 0.060 4, 0.042 7, 0.086 9, 0.068 4, 0.054 5, 0.037 0, 0.034 4, 0.076 9, 0.047 6, and 0.039 9, respectively. Salbutamol Sulfate Nebules Inhalation Solution has high rationality in pediatric clinical application. Conclusion The AHP-TOPSIS method was established to evaluate the rationality of the clinical use of Salbutamol Sulfate Nebules Inhalation Solution in pediatrics, and to provide guidance for its rational drug use.

R974

成都市医学科研课题（2021427）